{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-24-015083","form_type":"8-K","ticker":"PLSE","cik":"0001625101","company_name":"PULSE BIOSCIENCES, INC.","filed_at":"2024-05-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.301960+00:00","generated_at":"2026-06-02T18:42:30.748698+00:00","sec_items":["2.02","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Pulse Biosciences Q1 net loss $10.1M; FDA clears percutaneous electrode; plans $60M rights offering","bullets":["FDA 510(k) clearance for CellFX nsPFA Percutaneous Electrode for soft tissue ablation in percutaneous and intraoperative procedures.","CellFX nsPFA Cardiac Clamp 510(k) process ongoing; FDA requests clinical data; feasibility study submitted in Netherlands.","Board approved rights offering of up to $60M in units; record date moved to mid-June; fully subscribed adds $66M warrants.","GAAP net loss Q1 2024 $10.1M vs $9.8M year ago; cash $34.9M (down from $44.4M Dec 31, 2023).","Non-GAAP net loss $8.1M vs $8.6M prior year; Q1 cash used $9.5M including $2M annual bonus payouts."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-24-015083","json":"https://secwatch.observer/filing/0001437749-24-015083.json","markdown":"https://secwatch.observer/filing/0001437749-24-015083.md","text":"https://secwatch.observer/filing/0001437749-24-015083.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1625101/000143774924015083/0001437749-24-015083-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1625101/000143774924015083/plse20240321_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T18:42:30.748698+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"adf863e840ffbd5f420c9b8ef7452e46df3863ba","claim":"PULSE BIOSCIENCES, INC. reported the first quarter ended March 31, 2024 results: net income GAAP net loss for the three months ended March 31, 2024 was ($10.1) million compared to ($9.8) million for the three mon.","evidence_excerpt":"Pulse Biosciences, Inc. (the \"Company\") announced its financial and operational results for the fiscal quarter ended March 31, 2024.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1625101/000143774924015083/0001437749-24-015083-index.htm","confidence":1.0,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the first quarter ended March 31, 2024"},{"label":"Net income","value":"GAAP net loss for the three months ended March 31, 2024 was ($10.1) million compared to ($9.8) million for the three mon"},{"label":"Result","value":"reported results"}]}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}